Ligand Pharma (LGND) Tops Q2 EPS by 17c ; Offers Guidance
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $314.10 +4.17%
Revenue Growth %: -32.4%
Financial Fact:
Income (loss) before income taxes: 1.21M
Today's EPS Names:
OCCI, PMCB, BRID, More
Revenue Growth %: -32.4%
Financial Fact:
Income (loss) before income taxes: 1.21M
Today's EPS Names:
OCCI, PMCB, BRID, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.60, $0.17 better than the analyst estimate of $1.43. Revenue for the quarter came in at $47.63 million versus the consensus estimate of $43.74 million.
GUIDANCE:
Ligand Pharma sees FY2025 EPS of $6.70-$7.00, versus the consensus of $6.12. Ligand Pharma sees FY2025 revenue of $200-225 million, versus the consensus of $194 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Financial Group (JEF) Tops Q3 EPS by 8c
- Irenic Capital opposes Independence Realty's Centerspace deal - Bloomberg
- Trump says no sanctions relief was offered to Iran
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
